Zacks Research Issues Positive Estimate for Glaukos Earnings

Key Points

• Zacks Research raised Glaukos’ Q3 2026 EPS estimate to a loss of $0.13 per share from a prior estimate of $0.16, while forecasting a $0.03 profit for Q4 2026.
• Glaukos’ latest quarter exceeded expectations, with a loss of $0.14 per share versus the $0.21 consensus estimate and revenue of $185.6 million, up 49.6% year over year.
• Analyst sentiment remains positive: 12 analysts rate the stock Buy, with an average price target of $178.08, although executives and directors have sold shares totaling about $19.6 million over the past 90 days.

Glaukos Corporation (NYSE:GKOS - Free Report) - Research analysts at Zacks Research upped their Q3 2026 EPS estimates for shares of Glaukos in a report released on Wednesday, August 19th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings per share of ($0.13) for the quarter, up from their previous estimate of ($0.16). The consensus estimate for Glaukos' current full-year earnings is ($0.35) per share. Zacks Research also issued estimates for Glaukos' Q4 2026 earnings at $0.03 EPS, FY2026 earnings at ($0.43) EPS and Q1 2027 earnings at ($0.04) EPS.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.07. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The business had revenue of $185.61 million during the quarter, compared to the consensus estimate of $150.93 million. During the same period in the previous year, the firm posted ($0.24) earnings per share. Glaukos's revenue for the quarter was up 49.6% compared to the same quarter last year.

GKOS has been the topic of several other reports. Citigroup raised their price target on Glaukos from $175.00 to $188.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. William Blair reissued an "outperform" rating on shares of Glaukos in a research note on Tuesday, May 26th. Needham & Company LLC raised their target price on Glaukos from $150.00 to $201.00 and gave the stock a "buy" rating in a report on Thursday, July 30th. HC Wainwright boosted their target price on Glaukos from $168.00 to $195.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Finally, Wells Fargo & Company upped their price target on Glaukos from $138.00 to $178.00 and gave the company an "overweight" rating in a research note on Thursday, July 30th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $178.08.

Glaukos Price Performance

GKOS opened at $185.25 on Friday. The company has a fifty day moving average price of $156.20 and a two-hundred day moving average price of $131.24. The firm has a market capitalization of $10.93 billion, a PE ratio of -57.00 and a beta of 0.78. Glaukos has a 52 week low of $73.16 and a 52 week high of $191.62. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04.

Hedge Funds Weigh In On Glaukos

Several institutional investors and hedge funds have recently modified their holdings of GKOS. First Horizon Corp raised its position in shares of Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier's stock valued at $27,000 after purchasing an additional 223 shares during the period. Allworth Financial LP bought a new stake in shares of Glaukos during the 2nd quarter worth about $28,000. Los Angeles Capital Management LLC acquired a new position in Glaukos in the 4th quarter valued at about $28,000. Larson Financial Group LLC raised its holdings in Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock valued at $39,000 after acquiring an additional 132 shares during the period. Finally, Parallel Advisors LLC raised its holdings in Glaukos by 159.2% in the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier's stock valued at $40,000 after acquiring an additional 226 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Glaukos

In related news, Director Gilbert H. Kliman sold 2,500 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total transaction of $475,000.00. Following the completion of the transaction, the director owned 37,406 shares in the company, valued at approximately $7,107,140. This represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Alex R. Thurman sold 20,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $180.13, for a total value of $3,602,600.00. Following the sale, the chief financial officer owned 43,906 shares in the company, valued at approximately $7,908,787.78. This represents a 31.30% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 113,025 shares of company stock worth $19,600,006 in the last 90 days. Company insiders own 5.90% of the company's stock.

Key Stories Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: BTIG raised its price target to $202 from $193 and maintained a “Buy” rating, implying about 9% upside from the referenced $185.25 price. The upgrade reflects continued confidence in Glaukos’ growth outlook. Benzinga report
• Positive Sentiment: Analyst estimates from Zacks Research were raised broadly, including FY2027 EPS to $0.45 from $0.38 and FY2028 EPS to $1.70 from $1.56. Forecasts for several 2027 and 2028 quarters were also increased, signaling expectations for a transition toward stronger earnings. Glaukos analyst estimates
• Positive Sentiment: Glaukos’ iDose TR glaucoma implant and the Epioxa launch are driving record growth and contributed to higher 2026 guidance. Investors are also responding to the company’s expanding ophthalmology platform, product pipeline and potential for margin expansion. Zacks growth outlook article
• Neutral Sentiment: The company recently reported revenue of $185.6 million, up 49.6% year over year, and a quarterly loss of $0.14 per share that was better than expected. Glaukos remains unprofitable, but analysts expect positive EPS in future periods as revenue scales.
• Negative Sentiment: Director Gilbert H. Kliman sold 2,500 shares for approximately $475,000 at an average price of $190. The sale reduced his direct ownership by 6.26%, although he still held 37,406 shares afterward. SEC insider trading filing

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source